TY - JOUR
T1 - Recommendations for the management of autoinflammatory diseases
AU - Ter Haar, Nienke M.
AU - Oswald, Marlen
AU - Jeyaratnam, Jerold
AU - Anton, Jordi
AU - Barron, Karyl S.
AU - Brogan, Paul A.
AU - Cantarini, Luca
AU - Galeotti, Caroline
AU - Grateau, Gilles
AU - Hentgen, Veronique
AU - Hofer, Michael
AU - Kallinich, Tilmann
AU - Kone-Paut, Isabelle
AU - Lachmann, Helen J.
AU - Ozdogan, Huri
AU - Ozen, Seza
AU - Russo, Ricardo
AU - Simon, Anna
AU - Uziel, Yosef
AU - Wouters, Carine
AU - Feldman, Brian M.
AU - Vastert, Sebastiaan J.
AU - Wulffraat, Nico M.
AU - Benseler, Susanne M.
AU - Frenkel, Joost
AU - Gattorno, Marco
AU - Kuemmerle-Deschner, Jasmin B.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and ( paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptorassociated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with >80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD. This project is supported by a grant from European Agency for Health and Consumers (EAHC), grant number 2011 1202.
AB - Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and ( paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptorassociated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with >80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD. This project is supported by a grant from European Agency for Health and Consumers (EAHC), grant number 2011 1202.
UR - http://www.scopus.com/inward/record.url?scp=84942080292&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2015-207546
DO - 10.1136/annrheumdis-2015-207546
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 26109736
AN - SCOPUS:84942080292
SN - 0003-4967
VL - 74
SP - 1636
EP - 1644
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 9
ER -